H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Context Therapeutics (CNTX – Research Report) today and set a price target of $4.00. The company’s shares opened today at $0.99.
According to TipRanks, Bodnar is an analyst with an average return of -15.0% and a 26.32% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as SQZ Biotechnologies, Context Therapeutics, and Olema Pharmaceuticals.
Context Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $7.65 and a one-year low of $0.95. Currently, Context Therapeutics has an average volume of 183.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
Read More on CNTX:
- Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
- Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
- Context nominated CTIM-76 as candidate to target Claudin 6-positive cancers
- Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
- Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
